Lung fluid biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis

Abstract

BackgroundWith the development of new techniques to easily obtain lower respiratory tract specimens, bronchoalveolar lavage fluid and other lung fluids are gaining importance in pulmonary disease diagnosis. We aimed to review and summarize lung fluid biomarkers associated with acute respiratory distress syndrome diagnosis and mortality.MethodsAfter searching PubMed, Embase, Web of Science, and the Cochrane Library for articles published prior to January 11, 2018, we performed a meta-analysis on biomarkers for acute respiratory distress syndrome diagnosis in at-risk patients and those related to disease mortality. From the included studies, we then extracted the mean and standard deviation of the biomarker concentrations measured in the lung fluid, acute respiratory distress syndrome etiologies, sample size, demographic variables, diagnostic criteria, mortality, and protocol for obtaining the lung fluid. The effect size was measured by the ratio of means, which was then synthesized by the inverse-variance method using its natural logarithm form and transformed to obtain a pooled ratio and 95% confidence interval.ResultsIn total, 1156 articles were identified, and 49 studies were included. Increases in total phospholipases A2 activity, total protein, albumin, plasminogen activator inhibitor-1, soluble receptor for advanced glycation end products, and platelet activating factor-acetyl choline were most strongly associated with acute respiratory distress syndrome diagnosis. As for biomarkers associated with acute respiratory distress syndrome mortality, interleukin-1β, interleukin-6, interleukin-8, Kerbs von Lungren-6, and plasminogen activator inhibitor-1 were significantly increased in the lung fluid of patients who died. Decreased levels of Club cell protein and matrix metalloproteinases-9 were associated with increased odds for acute respiratory distress syndrome diagnosis, whereas decreased levels of Club cell protein and interleukin-2 were associated with increased odds for acute respiratory distress syndrome mortality.ConclusionsThis meta-analysis provides a ranking system for lung fluid biomarkers, according to their association with diagnosis or mortality of acute respiratory distress syndrome. The performance of biomarkers among studies shown in this article may help to improve acute respiratory distress syndrome diagnosis and outcome prediction.Electronic supplementary materialThe online version of this article (10.1186/s13054-019-2336-6) contains supplementary material, which is available to authorized users.

Defining the Inflammatory Microenvironment in the Human Cochlea by Perilymph Analysis: Toward Liquid Biopsy of the Cochlea

“…Plasminogen activator inhibitor-1 (PAI-1) is a pro-coagulant that is released by platelets and the endothelium in response to inflammation, damage, or ischemia and can be used as early marker for endothelial injury based on its inhibitory function of urokinase-like plasminogen activator (uPA) (38). Elevations of PAI-1 in bronchiolar lavage fluid is associated with experimentally-induced pulmonary fibrosis after thoracic radiation exposure (39) and in patients with lethal acute respiratory distress syndrome (40). Thus, the presence of PAI-1, uPA, and the high PAI-1/uPA ratio (>10) in perilymph may be an indicator for cochlear distress and damage.…”

Pulmonary fibrosis in the aftermath of the Covid-19 era (Review)

“…Previous studies in the literature have detected biomarkers of fibrogenesis in the bronchoalveolar fluid 24 h after the onset of ARDS that correlate with mortality. These include N-terminal pro-peptide of type III collagen, C-terminal pro-peptide of type I collagen, TGF-β, and alveolar fibroblasts and fibrocytes (24)(25)(26)(27). Fibrocytes have been shown to expand in the blood in the context of both physiologic wound repair and several diseases associated with fibrogenesis.…”

The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics

“…In the PI3K pathway, PKB can also stimulate the mammalian target of rapamycin (mTOR), resulting in the activation of STAT3 [28]. Moreover, evidence has revealed that stimulation of PKB/Akt, MAPK, STAT3, and NF-кB prompts a wide range of inflammatory responses and pathological states in different disorders such as severe pneumonia and ARDS [29,30] (Fig. 1).…”